Varex Imaging (VREX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Aug, 2026Executive summary
Teledyne Technologies will acquire all outstanding shares of Varex Imaging for $18.90 per share in cash, valuing the transaction at approximately $1.1 billion including equity awards and net debt as of April 3, 2026.
The merger was unanimously approved by both companies' boards and is expected to close in early 2027, subject to regulatory and shareholder approvals.
Varex will become a wholly owned subsidiary of Teledyne, and its shares will be delisted from Nasdaq and deregistered under the Exchange Act after closing.
The transaction is anticipated to provide a substantial premium to Varex shareholders and create complementary product offerings with minimal overlap.
Voting matters and shareholder proposals
Varex shareholders will vote on the adoption of the Merger Agreement at a special meeting, with approval requiring a majority of outstanding shares.
A proxy statement will be filed and distributed to shareholders after SEC clearance.
The company is subject to a “no shop” provision but may consider superior proposals before shareholder approval, subject to a $25.3 million termination fee if the agreement is terminated for such a proposal.
Board of directors and corporate governance
The Varex board unanimously approved the merger and recommends shareholder approval.
After the merger, the directors and officers of the Merger Sub will become the initial directors and officers of the surviving corporation.
Latest events from Varex Imaging
- Shareholders will vote on Varex's merger with Teledyne, with closing expected in early 2027.VREX
Proxy filing - Shareholders will vote on a proposed acquisition by Teledyne Technologies, closing in early 2027.VREX
Proxy filing - Shareholders will vote on a proposed acquisition by Teledyne, expected to close in early 2027.VREX
Proxy filing - Shareholders will vote on a proposed acquisition by Teledyne, expected to close in early 2027.VREX
Proxy filing - Quarterly revenue up 4% YoY to $211M, net income rebounded, and merger with Teledyne announced.VREX
Q3 2026 - Annual guidance, India ramp, photon counting, and AI drive growth and strategic flexibility.VREX
Jefferies Global Healthcare Conference 2026 - Q2 FY26 revenue rose 1–1.5% to $216M, with non-GAAP EPS at $0.21 and lower leverage from refinancing.VREX
Q2 2026 - Photon counting and industrial growth offset medical softness, with gradual China recovery expected.VREX
Jefferies 2024 Global Healthcare Conference - Q1 revenue up 5% to $200M, margin 35%, strong security orders, and Q2 growth outlook.VREX
Q1 2025